inPractice® - Naltrexone

Special Considerations and Clinical Management of HIV in Patients With Substance Use Disorder

Author: Frederick L. Altice, MD (More Info)
Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
Last Reviewed: 2/5/20 (What's New)

Summary

Naltrexone is an opiate-receptor antagonist used in the treatment of opioid dependence^{[Greenstein 1983; Roth 1997; Lobmaier 2008]}
Use among people with HIV and substance use disorder is discouraged as methadone and buprenorphine have higher retention rates^{[Stotts 2009]}
In 2010, the FDA approved extended-release naltrexone, administered as a monthly intramuscular injection, for the treatment of opioid dependence^{[Gastfriend 2011]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Initial Antiretroviral Therapy, IV Drug Use, Special Populations, Treatment Complications